secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2021-10-19T23:59:59+00:00
Accession:  0001447362-21-000239
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences to acquire Cernostics for up to $80M; expands into GI diagnostics with TissueCypher
--------------------------------------------------------------------------------

- Upfront consideration of $30M (cash or $20M cash + $10M stock at Castle's discretion); up to $50M in milestones based on 2022 performance.
- Cernostics' TissueCypher Barrett's Esophagus Assay is first precision medicine test to predict progression to esophageal cancer in BE patients.
- Deal expands Castle's estimated U.S. TAM by approximately $1B, complementing its dermatologic franchise.
- Transaction expected to close prior to year-end 2021; Cernostics management to remain; operations stay in Pittsburgh.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736221000239/0001447362-21-000239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736221000239/cstl-20211018.htm
  HTML page:      https://secwatch.observer/filing/0001447362-21-000239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer